Grace Therapeutics (NASDAQ:GRCE) is a clinical-stage biopharmaceutical company dedicated to advancing novel dermatological therapies harnessing the human microbiome. The company pioneers live-microbe-based topical treatments designed to restore skin health and address unmet needs in conditions such as acne vulgaris, rosacea and atopic dermatitis. By leveraging proprietary discovery platforms, Grace Therapeutics seeks to identify and develop microbial strains that deliver targeted therapeutic benefits, setting it apart in the evolving field of microbiome modulation.
The company’s lead candidate, B244, is a live biotherapeutic topically formulated to repopulate key commensal bacteria on the skin and modulate inflammatory pathways implicated in inflammatory acne and rosacea. Beyond B244, Grace Therapeutics’ pipeline includes programs targeting dandruff and seborrheic dermatitis, as well as the development of novel formulations aimed at enhancing patient compliance and formulation stability. Early clinical data have shown promising signs of efficacy and skin microbiome rebalancing, supporting advancement into later-stage studies.
Founded in 2019 and headquartered in Dallas, Texas, Grace Therapeutics was built upon collaborative research with academic institutions and industry partners focused on microbiome science. The company’s research facilities and manufacturing partnerships span the United States, with plans to expand into European and Asian markets pending regulatory pathway confirmations. Through strategic alliances and licensing agreements, Grace Therapeutics is constructing a global footprint for commercialization and distribution of its therapeutics.
Grace Therapeutics’ leadership team combines expertise in microbiology, dermatology and pharmaceutical development. Armin Morad, co-founder and Chief Executive Officer, brings over two decades of experience in biotech venture creation and life-science investment. Chief Scientific Officer Dr. Deirdre Meldrum oversees translational research and pipeline strategy, while Chief Financial Officer Michael Smith manages corporate finance, capital markets engagement and strategic planning. Together, the team is guided by a commitment to innovation and patient-centric care in dermatological treatment.
